Anti‐ KIT Barzolvolimab for Chronic Spontaneous Urticaria
Allergy · 2025-08 · 80 (8) · 2178-2186
DOI: 10.1111/all.16598 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Allergy, online erschienen am 26.05.2025. Verfasst von Marcus Maurer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Chronic Urticaria, Proto-Oncogene Proteins c-kit, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Celldex Therapeutics.
Abstract (Originalsprache)
Background
Chronic spontaneous urticaria (CSU) is characterized by mast cell (MC)‐mediated wheals and/or angioedema without identifiable triggers and is driven by MC activation. Barzolvolimab—a monoclonal anti‐KIT antibody—depletes MCs by inhibiting activation of KIT by stem cell factor. We evaluated multiple ascending doses in patients with CSU.
Methods
Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up in four sequentially enrolled cohorts (randomized 4:1 barzolvolimab:placebo): 0.5 mg/kg, Q4W ( n = 9); 1.5 mg/kg, Q4W ( n = 8); 3 mg/kg, Q8W ( n = 9); and 4.5 mg/kg, Q8W ( n = 9). Primary and secondary objectives were safety and disease activity (UAS7 and urticaria control test [UCT]). Pharmacokinetics and pharmacodynamics were assessed.
Results
Patients had high mean (range) baseline CSU activity, with UAS7 = 29.6 (16.3–42.0) for barzolvolimab‐treated, UAS7 = 35.8 (19.0–42.0) for placebo‐treated, and 44% prior omalizumab use. Multiple doses of barzolvolimab were well tolerated. Hair color change was the commonest adverse event in barzolvolimab‐treated patients. Across barzolvolimab doses, rapid symptom reduction within 1 week was observed and sustained during 12 weeks; 71% of patients achieved a well‐controlled (UAS7 ≤ 6) response and 57% a complete response (UAS7 = 0). Additionally, 77% of barzolvolimab‐treated patients achieved a well‐controlled response (UCT ≥ 12) and 43% a complete response (UCT = 16) by Week 12. The kinetics of disease activity paralleled tryptase suppression, indicative of MC inhibition. Patients with and without prior omalizumab treatment responded similarly.
Conclusions
This study supports barzolvolimab as a promising treatment for CSU.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Fraunhofer Institute for Translational Medicine and Pharmacology, Immunology and Allergology, Berlin, Germany.
- Clinical Research Center of Alabama, AllerVie Health, University of Alabama, Birmingham, and VA Medical Center, Birmingham, Alabama, USA.
- The Allergy Group and Treasure Valley Medical Research, Boise, Idaho, USA.
- Celldex Therapeutics, Hampton, New Jersey, USA.
- University of Cincinnati, Cincinnati, Ohio, USA.
ORCID-Profile: Marcus Maurer, Martin Metz, Jonathan A Bernstein
Förderung
- Celldex Therapeutics
Zitieren
APA
Maurer, M., Metz, M., Anderson, J., Talreja, N., Young, D., Crowley, E., Heath-Chiozzi, M., Ma, R., Paradise, E., Hawthorne, T., Alvarado, D., & Bernstein, J. A. (2025). Anti‐ KIT Barzolvolimab for Chronic Spontaneous Urticaria. Allergy, 80(8), 2178-2186. https://doi.org/10.1111/all.16598
Vancouver
Maurer M, Metz M, Anderson J, Talreja N, Young D, Crowley E, et al. Anti‐ KIT Barzolvolimab for Chronic Spontaneous Urticaria. Allergy. 2025;80(8):2178-2186. doi:10.1111/all.16598
BibTeX
@article{Maurer2025,
author = {Maurer, Marcus and Metz, Martin and Anderson, John and Talreja, Neetu and Young, Diane and Crowley, Elizabeth and Heath-Chiozzi, Margo and Ma, Rick and Paradise, Elsa and Hawthorne, Thomas and Alvarado, Diego and Bernstein, Jonathan A},
title = {Anti‐ KIT Barzolvolimab for Chronic Spontaneous Urticaria},
journal = {Allergy},
year = {2025},
volume = {80},
number = {8},
pages = {2178--2186},
doi = {10.1111/all.16598}
}
EUVIMED